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ABSTRACT
Background. Early diagnosis of chronic kidney disease (CKD)
facilitates best management in primary care. Testing coverage of
those at risk and translation into subsequent diagnostic coding
will impact on observed CKD prevalence. Using initial data
from 915 general practitioner (GP) practices taking part in a
UK national audit, we seek to apply appropriate methods to
identify outlying practices in terms of CKD stages 3–5 preva-
lence and diagnostic coding.
Methods. We estimate expected numbers of CKD stages 3–5
cases in each practice, adjusted for key practice characteristics,
and further inﬂate the control limits to account for overdispersion
related to unobserved factors (including unobserved risk factors
for CKD, and between-practice differences in coding and testing).
Results. GP practice prevalence of coded CKD stages 3–5 ranges
from 0.04 to 7.8%. Practices differ considerably in coding of CKD
in individuals where CKD is indicated following testing (ranging
from 0 to 97% of those with and glomerular ﬁltration rate
<60 mL/min/1.73 m2). After adjusting for risk factors and over-
dispersion, the number of ‘extreme’ practices is reduced from 29
to 2.6% for the low-coded CKD prevalence outcome, from 21 to
1% for high-uncoded CKD stage and from 22 to 2.4% for low
total (coded and uncoded) CKD prevalence. Thirty-one practices
are identiﬁed as outliers for at least one of these outcomes. These
can then be categorized into practices needing to address testing,
coding or data storage/transfer issues.
Conclusions.GP practice prevalence of coded CKD shows wide
variation. Accounting for overdispersion is crucial in providing
useful information about outlying practices for CKD
prevalence.
Keywords: audit, chronic kidney disease, outliers, overdisper-
sion, prevalence
INTRODUCTION
Chronic kidney disease (CKD) is a precursor to subsequent
deterioration in kidney function and adverse outcomes associ-
ated with this decline [1]. It is therefore of growing importance
to characterize and understand differences in diagnosis of this
condition in primary care in order to improve management and
outcomes for those with CKD.
Factors known to be associated with developing CKD
include increasing age, diabetes, hypertension and previous car-
diovascular events [2–6]. Since 2006, general practitioners
(GPs) in England andWales have been incentivized to maintain
a register of those with CKD stages 3–5 through the NHS
Quality and Outcomes Framework (QOF). GPs can add
patients to their register by assigning an electronic ‘read code’.
Most prescribing software systems used by GPs rely on the pres-
ence of coded CKD, and not on serum creatinine or estimated
glomerular filtration rate (eGFR) values. If patients are not
coded for CKD then, depending on the software used, the
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inbuilt safety alerts related to adapting drug choice or dosing to
level of renal function may not work. QOF data suggest that
there is substantial practice variation in the proportion of
patients with read codes for CKD stages 3–5, with prevalences
ranging from 0.01 to 27% [7]. The next steps are to investigate
the sources of this heterogeneity and to identify outliers for
CKD prevalence, with a view to contacting individual practices
to improve testing for and/or coding of CKD (and thus care and
management of these patients) [8, 9].
We use initial data from a UK national CKD audit to illus-
trate the importance of accounting for large between-practice
variability when seeking to identify the most extreme outlying
practices for CKD prevalence.
MATERIALS AND METHODS
Subjects
GP practices submitting baseline data to the National
Chronic Kidney Disease Audit (NCKDA) between March and
12 November 2015 are included in the analysis. More informa-
tion on the audit can be found on the NCKDA website [10].
Data were collected for 915 practices in England and Wales
using Informatica software. The software is compatible with the
range of GP clinical computer systems and can directly extract
anonymized-coded clinical data, including diagnostic and labo-
ratory test results, from the patient record.
Baseline data were extracted for all individuals within a
practice aged 18þ years with either a QOF code for CKD (any
stage; for list of codes see Supplementary Table S1 or with a
risk factor/renal disease diagnosis at least 1 year prior to data
extraction. This latter group includes those with diagnosed
genetic renal conditions or any of the following: hypertension,
diabetes, gout, ischaemic heart disease, congestive cardiac fail-
ure, cerebrovascular disease, peripheral arterial disease, kidney
stones, prostatic hypertrophy, prescription of lithium/tacroli-
mus/cyclosporin in past year, systemic lupus erythematosus
and other connective tissue disorders. Retrospective creatinine
eGFR measurements were also obtained for all these individu-
als, together with baseline characteristics including age, sex
and index of multiple deprivation (IMD), a validated measure
of area socio-economic deprivation [11]. Where available,
complete practice age–sex distribution data were also
obtained. Practices were given an email summary of their data
after the initial extraction (round 1) to allow the practices to
check the data for errors and amend these. After 3 months, a
second and final extraction of data on CKD stages 3–5 preva-
lence were taken (round 2). It is the initial round 1 data that
are used for the analyses in this article, and results shown here
use anonymized practice data. The full results of the audit,
using round 2 data, will be published in a report at the end of
2016.
This work aims to identify and compare outlying practices in
terms of three key outcomes of interest: (i) prevalence of read-
coded CKD (stages 3–5), (ii) prevalence of uncoded CKD
amongst those with eGFR evidence of CKD stages 3–5 and (iii)
total CKD prevalence (combining those with coded and
FIGURE 1: Scatter plot showing increase in standardized CKD
prevalence after inclusion of uncoded CKD, for 756 practices for
whom prevalence can be calculated from list size data.
Table 1. Summary of practice-level characteristics
Practice-level characteristics No. of practices with data (/915)a Median (IQR)
List size (including under 18s) 756 7456 (4568, 10 310)
Median age (years)b 756 40 (40, 45)
Female (%) 756 49.4 (48.4, 50.6)
Median index of multiple deprivationc 601 17 179 (10 575, 22 866)
Black ethnicity (%) 756 0.27 (0, 1.27)
Diabetes (%) 756 6.1 (5.2, 7.2)
Hypertension (%) 756 17.7 (15.0, 20.4)
CVD (%) 756 6.2 (4.9, 7.4)
Testing in at-risk population (%) 915 92.7 (90.6, 94.2)
Mean (SD)
Age–sex standardized CKD prevalence (%) 756 3.1 (1.2)
Proportion with uncoded CKD if GFR evidence of CKD (%) 915 35.8 (17.6)
Combined coded and uncoded age–sex standardized CKD prevalence (%) 756 4.3 (1.2)
aOnly 756 practices had list size data available.
bUsing all ages list size data to identify median age in practice, using mid-points of 5-year age bands.
cAmongst patients with CKD or at high risk from CKD only. Estimated only for those practices that also have list size data (i.e. excludes 15 practices with IMD data, but no list
size data).
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uncoded CKD stages 3–5). The recording of urinary protein
tests is generally poor; we therefore do not report results on pro-
teinuria in this article.
(i) Read-coded CKD prevalence
Practice-coded CKD prevalence is calculated using read
codes for CKD stages 3–5 and list size data for all ages.
Direct standardization is carried out using the GP prac-
tice database of the age–sex distribution (using 5-year age
bands) for GP practices in England [12]. Note that this
calculation assumes no CKD in under 18s (as data are not
collected for this group in the audit); however, this is not
unreasonable as the number of such cases within a prac-
tice is likely to be negligible.
(ii) Uncoded CKD amongst those with eGFR evidence of
CKD
Patients with eGFR evidence of CKD are defined as those for
whom either: (a) the two most recent eGFR measurements
are both<60 mL/min/1.73m2 and where at least 3 months
have elapsed between measurements (the most recent meas-
urement must be in the last 2 years and both measurements
since 1 January 2008), or (b) the most recent eGFR meas-
urement (since 1 January 2008, in last 2 years) is<60
mL/min/1.73m2, and this is the only eGFR measure-
ment ever taken. Individuals meeting one of these crite-
ria are then defined as having uncoded CKD if they do
not have a QOF code for stages 3–5 CKD.
(iii) Total CKD prevalence
The number of individuals with (a) coded and (b)
uncoded CKD are combined to obtain a practice total
CKD prevalence. This is then age–sex standardized in the
same way as measure (i).
Statistical methods
Funnel plots are produced for each of the three outcomes of
interest (i)–(iii), with a view to identifying outlying practices.
However, when seeking to identify outlying practices, it would
be naı¨ve to take the view that there is a single common target
CKD prevalence that all practices should be compared to.
Rather, there are a range of factors, both observed and unob-
served, that must be taken into account.
FIGURE 2: (a) Crude funnel plot of standardized coded CKD prevalence. (b) Funnel plot of standardized coded CKD prevalence. Expected
cases adjusted for practice median IMD and proportion of practice tested for CKD and proportion with black ethnicity, diabetes, hypertension
and CVD. (c) Funnel plot of standardized coded CKD prevalence, with 10% winsorization and adjustment for overdispersion using multiplica-
tive random effects. Expected cases adjusted for practice median IMD and proportion of practice tested for CKD and proportion with black
ethnicity, diabetes, hypertension and CVD.
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Observed factors
Target prevalences for each practice should ideally reflect
underlying differences in the practice populations, and the
acceptable range of values should also reflect the population size
from which the observed value is derived. This can be achieved
using a funnel plot based on observed–expected cases against
expected cases. Expected cases for outcomes (i) and (iii) for each
practice were back-calculated from a logistic regression model
for the practice proportion of cases, adjusted for practice-level
proportions of individuals with diabetes, hypertension, cardio-
vascular disease (CVD), black ethnicity and median IMD, and
the proportion of at-risk patients undergoing testing for CKD.
For outcome (ii), expected cases were taken from a logistic
regression model adjusted only for black ethnicity, since there
was no a priori reason to expect coding given eGFR measure-
ment to be associated with any other factor.
Where data are not available on all explanatory variables
used in calculating the expected cases for some practices, unad-
justed cases (crude mean) are plotted instead—these practices
are identified on the funnel plots using red points.
Unobserved factors. Wide variation between practices in
terms of both testing and coding of CKD results in considerable
overdispersion of all of these outcomes. This phenomenon has
been described previously in between-practice comparisons of
similar types of outcomes [13, 14]. Some of this overdispersion
can be accounted for by adjusting the contours for factors
related to the between-practice heterogeneity [13]. We have
opted to apply multiplicative random effects methods [15] here
as this approach is more conservative with respect to practices
with very small numbers of expected cases. Contours were addi-
tionally winsorized by 10% in order to further reduce the
FIGURE 3: (a) Crude funnel plot of proportion of uncoded CKD in those with GFR evidence of CKD, without adjusting for overdispersion.
(b) Funnel plot of proportion of uncoded CKD in those with GFR evidence of CKD, with 10% winsorization and adjustment for overdispersion
using multiplicative random effects. Expected cases adjusted for proportion of practice with black ethnicity.
ii154 L.G. Kim et al.
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potential influence of extreme values on the contours whilst still
retaining the same number of z-scores. This is achieved by rank-
ing the z-values calculated above, and replacing the bottom 10%
with the value of the 10th centile and top 10% with the value of
the (100–10)th centile.
RESULTS
In total, 915 GP practices recruited at round 1 are included in
the analysis of uncoded CKD [outcome (ii)] and 756 of these
practices with list size data available are included in the analysis
of prevalence [outcomes (i) and (iii)]. Basic practice characteris-
tics are summarized in Table 1. The large heterogeneity in age–
sex standardized CKD prevalence is illustrated in
Supplementary Figure S1; it is also clear from these plots that
key practice-level characteristics such as the proportion of
patients with diabetes only explain around 20% of the between-
practice differences in prevalence (R2¼21.6%, Appendix
Table S2).
Figure 1 shows the increase in CKD prevalence after inclu-
sion of uncoded cases in whom there is biochemical evidence of
CKD, by practice. Whilst the majority of practices increase by
an additional 0–1% after this adjustment, uncoded cases
increase the prevalence by over 5% in a small number of
practices.
Funnel plots for each of the outcomes of interest using
crude and adjusted contours are shown in Figures 2–4 and
Supplementary Figure S2, with accompanying numbers of
outliers given in Table 2. It is clear that neither the crude con-
tours nor those with expected cases adjusted for known risk
factors are useful in identifying outliers for CKD prevalence.
This reflects the large underlying between-practice heteroge-
neity in a range of factors that is not accounted for in the cal-
culation of expected cases. This will include both
identification of the at-risk population and coding of CKD as
well as unmeasured practice population characteristics (the
proportion of the identified at-risk population who are tested
is adjusted for here). This heterogeneity must be taken into
account when seeking to identify practices that are really
extreme in terms of these outcomes. This is achieved by
increasing the contours by a factor (u^) that is related to the
percentage of overdispersion around the target [15] (see
Supplementary Table S3).
These methods have enabled the identification of a small
number of practices that warrant further investigation (Table 3
FIGURE 4: Funnel plot of combined coded and uncoded standardized CKD prevalence, with 10% winsorization and adjustment for overdis-
persion using multiplicative random effects. Expected cases adjusted for practice median IMD and proportion of practice tested for CKD and
proportion with black ethnicity, diabetes, hypertension and CVD.
Table 2. Number of practices identiﬁed as outliers for CKD prevalence
n No. of outlying practices identified at 3 SDs (% of practices analysed)
Crude contours Adjusted contoursa
Low-coded CKD 756 223 (29) 20 (2.6)
High-uncoded CKD 915 194 (21) 9 (1.0)
Low combined coded and uncoded CKD 756 163 (22) 18 (2.4)
aContours adjusted for 10% winsorization and overdispersion; expected cases adjusted for practice-level diabetes, CVD, hypertension, black ethnicity, IMD and testing (black ethnicity
only for uncoded CKD) where all data are available, otherwise unadjusted cases are used.
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|and Figure 5). Such practices can generally be categorized in
order to tailor quality improvement:
(i) Outlier for low-coded/combined CKD prevalence and
for high-uncoded CKD
Suggests that coding could be improved.
(ii) Outlier for low-coded/combined CKD prevalence but
not for high-uncoded CKD
(a) This may still be a coding issue, or be due to particular
practice characteristics: coding issue, but not an outlier
for this due to low numbers tested. Low testing may
indicate that testing of those at risk could be improved,
or may be due to low numbers at risk related to low
practice mean age/small list size (practice 525, 788).
(b) expected cases do not adequately reﬂect practice
characteristics, either due to unobserved practice
characteristics or the model not fully capturing the
reduction in expected cases for practices with
extreme characteristics [practice 92 (low age, high
black ethnicity, low IMD), 827 (low testing)].
(iii) Not an outlier for low prevalence but outlier for high-
uncoded CKD
Suggests some improvements can still be made to cod-
ing. Some of these practices may be unidentiﬁed outliers
for CKD prevalence (due to missing list size data), which
would place them in group (i).
(iv) Either (i) or (ii) together with very low diabetes, hyper-
tension and/or CVD
Suggests more a general issue with coding and/or data
extraction for diabetes and vascular disease as well as CKD.
For these data, 4 practices are identified in group A, 4 in group
B, 5 in group C and 18 practices are in group D. This means
that a sizeable majority of outliers identified (18/31 practices)
are likely to be due to poor data quality, with smaller groups
identified as needing to address issues with coding.
DISCUSSION
It is good practice to seek to identify outliers that may be able to
improve their CKD coding compared with the rest of the practi-
ces in the analysis. In reality, this means we want to identify a
small number of extreme outlying practices in terms of
Table 3. Summary of outlier practices identiﬁed using control limits accounting for overdispersion
Practice ID Mean
age (years)
Observed
cases
List size Outlier low
prevalence
Outlier
high-
uncoded
CKD
Outlier low
total CKD
Low
testinga
High
IMDa
Low
diabetesa
Low hta Low
CVDa
Group
142 42.5 99 11 769   A
448 45.8 46 5425   A
454 46.9 124 8140   A
581 45.1 79 6230   A
92 36.9 174 15 170  BL B
525 39.3 14 5477  BL B
788 39.1 23 7874  BL BL B
827 43.5 192 8900  BL  B
100 44.9 280 9455   C
164 37.7 240 11 990 BL   C
796 - 355 -  C
892 - 261 -  C
909 - 132 -  C
57 43.2 23 6060 BL      D
155 47.6 39 12 700      D
266 42.7 136 10 390 BL     D
388 45.9 257 28 200       D
408 41.9 9 6916       D
459 44.4 6 12 190       D
477 49.3 91 6280 BL     D
568 42.1 112 12 120      D
577 37.9 4 8800      D
611 51.1 165 15 500      D
634 44.5 4 2622 BL      D
640 54.3 263 28 100      D
651 47.7 197 20 800      D
738 50.5 166 18 300      D
772 38.0 15 7716      D
804 45.4 338 26 800      D
822 42.0 240 20 100 BL     D
332 39.1 256 16 340 BL  BL BL D
aLow diabetes:<10th centile¼<4%; low hypertension (ht):<10th centile¼<11%; low CVD:<10th centile¼<3.5%; high IMD:>90th centile¼ 26 000; low testing:<10th centi-
le¼<88% of at-risk.
BL¼ borderline (outlier at 2 SD).
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||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
|performance in order to focus efforts for improvement.
However, there is generally large between-practice heterogene-
ity in outcomes in primary care that rely on a range of processes
(here, identification of at-risk patients, testing and coding) as
well as underlying risk factors for the outcome itself. This heter-
ogeneity results in substantial overdispersion of prevalences,
hampering efforts to identify outlying practices. It is therefore
imperative that an appropriate strategy is applied in order to
account for this when carrying out such analyses.
Identification of outlying practices requires comparison of
practice outcomes with a defined target. However, this target
should reflect both observed underlying risk factors and unob-
served influences resulting in overdispersion; such influences
may include unobserved risk factors and differences in the
processes relating to estimating the outcome. This practice-
specific target estimation can be carried out by direct adjust-
ment for known risk factors at practice level, and by additionally
accounting for overdispersion in the outcome. For CKD preva-
lence, this has resulted in a substantial reduction of the number
of outlying practices identified, which in turn focusses attention
on those practices where there may be errors in data acquisition
or deficiencies in identifying and coding CKD cases.
There are a number of limitations to our work. Our data are
limited to practices using the Informatica Auditþ software,
and as such these practices may represent a self-selecting sub-
population of practices who are most interested in quality
improvement. In light of this, it is reasonable to interpret the
data presented here as potentially the best possible case
FIGURE 5: (a) Funnel plot of standardized CKD prevalence, with outlying practices highlighted by group. Contours with 10% winsorization
and adjustment for overdispersion using multiplicative random effects. Expected cases adjusted for practice median IMD and proportion of
practice tested for CKD and proportion with black ethnicity, diabetes, hypertension and CVD. (b) Funnel plot of uncoded CKD, with outlying
practices highlighted by group. Contours with 10% winsorization and adjustment for overdispersion using multiplicative random effects.
Expected cases adjusted for black ethnicity.
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scenario for the UK. The observed mean practice age- and
sex-standardized prevalence of coded CKD in this sample of
915 practices in England and Wales (3.1%) is lower than
prevalences previously reported for studies in other countries
[16]. That this was observed despite the incentives of QOF
coding may be due to a number of reasons, including the
increased complexity of CKD coding and the presence of
other codes and flags for medication alerts. However, esti-
mates of total CKD prevalence based on eGFR measurements
from UK primary care data do not differ greatly from those
based on nationally representative samples [17]. Our study
defined CKD prevalence as having two recorded measure-
ments of eGFR<60 mL/min/1.73m2 more than 3 months
apart, and included all individuals in each practice with,
therefore, a lower mean age than samples used for other prev-
alence estimates [16]. Differences in underlying risk factors,
identifying at-risk patients, and in testing and diagnosing of
CKD are also likely to vary significantly between countries.
Although generalizability to other health systems is some-
what limited due to differing practice software systems and
funding incentives, the dominant issue is likely to be the high
degree of variability of CKD coding and care especially
amongst those without diabetes.
The clear strength of this study lies in the large sample of
practices, representing an underlying population of around
6 million patients. This audit provides a good snap-shot of
the quality of routine CKD data in primary care. We have
used these initial pilot data to demonstrate the importance of
accounting for between-practice variability in epidemiologi-
cal studies investigating CKD. Without appropriate handling
of this heterogeneity, findings from large primary care data
on CKD will be confounded by individual doctor’s manage-
ment of CKD.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
journals.org.
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